TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06244771: A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Sponsor: Frontier Medicines Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 293 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$667,590

Rescue Site Savings

+$431,970

Unlock Full NCT06244771 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06244771 Rescue Dossier →